Marlene M. Rayner

Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors

Patrick Y. S. Lam, Prabhakar K. Jadhav, Charles J. Eyermann et al. · Science · 1994 · 836 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

Cyclic HIV Protease Inhibitors:  Synthesis, Conformational Analysis, P2/P2‘ Structure−Activity Relationship, and Molecular Recognition of Cyclic Ureas

Patrick Y. S. Lam, Yu Ru, Prabhakar K. Jadhav et al. · Journal of Medicinal Chemistry · 1996 · 170 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

C. Nicholas Hodge, Paul E. Aldrich, Lee T. Bacheler et al. · Chemistry & Biology · 1996 · 148 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +16

Preparation and Structure−Activity Relationship of Novel P1/P1‘-Substituted Cyclic Urea-Based Human Immunodeficiency Virus Type-1 Protease Inhibitors

David A. Nugiel, Kim Jacobs, Tabitha V. Worley et al. · Journal of Medicinal Chemistry · 1996 · 106 citations · Full text

Pharmacy, Biochemistry, Medicinal Chemistry +11

Potent cyclic urea HIV protease inhibitors with benzofused heterocycles as P2/P2′ groups

James D. Rodgers, Barry L. Johnson, Haisheng Wang et al. · Bioorganic & Medicinal Chemistry Letters · 1996 · 102 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14